Total Payments
$24,763
2024 Payments
$11,342
Companies
21
Transactions
49
Medicare Patients
8,547
Medicare Billing
$4.2M
Payment Breakdown by Category
Consulting$18,049 (72.9%)
Other$3,300 (13.3%)
Food & Beverage$3,158 (12.8%)
Travel$156.36 (0.6%)
Education$99.99 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $18,049 | 9 | 72.9% |
| Food and Beverage | $3,158 | 30 | 12.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,500 | 1 | 6.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,150 | 5 | 4.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $500.00 | 1 | 2.0% |
| Travel and Lodging | $156.36 | 1 | 0.6% |
| Honoraria | $150.00 | 1 | 0.6% |
| Education | $99.99 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,455 | 4 | $0 (2024) |
| Acceleron Pharma, Inc. | $4,225 | 1 | $0 (2021) |
| SOBI, INC | $4,112 | 3 | $0 (2024) |
| Incyte Corporation | $2,789 | 3 | $0 (2024) |
| National Marrow Donor Program | $2,493 | 9 | $0 (2024) |
| Bavarian Nordic A/S | $2,020 | 1 | $0 (2023) |
| Celgene Corporation | $1,500 | 1 | $0 (2023) |
| Kite Pharma, Inc. | $562.77 | 8 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $302.32 | 4 | $0 (2024) |
| Genentech, Inc. | $196.85 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,342 | 19 | E.R. Squibb & Sons, L.L.C. ($4,941) |
| 2023 | $7,478 | 12 | Incyte Corporation ($2,763) |
| 2022 | $431.49 | 3 | National Marrow Donor Program ($356.36) |
| 2021 | $4,503 | 3 | Acceleron Pharma, Inc. ($4,225) |
| 2020 | $604.45 | 4 | E.R. Squibb & Sons, L.L.C. ($500.00) |
| 2019 | $253.85 | 4 | GENZYME CORPORATION ($98.34) |
| 2018 | $150.13 | 4 | GENZYME CORPORATION ($97.37) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | SOBI, INC | VONJO (Drug) | Consulting Fee | Cash or cash equivalent | $3,700.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/09/2024 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $41.69 | General |
| 12/07/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $71.63 | General |
| 12/07/2024 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $26.16 | General |
| 12/06/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $211.94 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,865.00 | General |
| 10/17/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $771.93 | General |
| 10/11/2024 | National Marrow Donor Program | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| 10/01/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $121.86 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $111.34 | General |
| Category: Oncology | ||||||
| 08/07/2024 | SOBI, INC | VONJO (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/25/2024 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $123.03 | General |
| 07/17/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $115.71 | General |
| Category: CELLT | ||||||
| 07/03/2024 | National Marrow Donor Program | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $200.00 | General |
| 06/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,076.00 | General |
| 05/23/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Oncology | ||||||
| 04/28/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $214.51 | General |
| 03/28/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $114.53 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $26.29 | General |
| Category: Hematology/Oncology | ||||||
| 10/20/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $78.69 | General |
| 09/25/2023 | Celgene Corporation | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,500.00 | General |
| 09/01/2023 | Bavarian Nordic A/S | — | Consulting Fee | Cash or cash equivalent | $2,020.00 | General |
| 08/18/2023 | National Marrow Donor Program | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| 07/27/2023 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $111.51 | General |
| 07/26/2023 | Genentech, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $196.85 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 57 | 2,188 | 71,060 | $5.3M | $1.0M |
| 2022 | 55 | 2,189 | 64,975 | $6.4M | $1.3M |
| 2021 | 49 | 2,203 | 61,848 | $4.9M | $1.1M |
| 2020 | 54 | 1,967 | 41,865 | $3.3M | $774,963 |
Total Patients
8,547
Total Services
239,748
Medicare Billing
$4.2M
Procedure Codes
215
All Medicare Procedures & Services
215 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 44 | 10,402 | $1.9M | $392,789 | 20.4% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 26 | 5,400 | $1.0M | $205,810 | 20.0% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 15 | 4,900 | $557,510 | $115,818 | 20.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 21 | 2,040 | $185,547 | $37,611 | 20.3% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 17 | 3,900 | $199,023 | $36,808 | 18.5% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 15 | 920 | $125,798 | $32,506 | 25.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 208 | 246 | $213,774 | $23,911 | 11.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 43 | 156 | $82,712 | $20,752 | 25.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 65 | 207 | $93,150 | $19,756 | 21.2% |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 2023 | 11 | 900 | $163,718 | $18,600 | 11.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 43 | 182 | $82,264 | $17,051 | 20.7% |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 2023 | 13 | 168 | $75,447 | $15,632 | 20.7% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 13 | 6,270 | $68,467 | $14,719 | 21.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 147 | 369 | $79,704 | $4,424 | 5.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 63 | 82 | $36,572 | $3,996 | 10.9% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 24 | 30 | $29,790 | $3,991 | 13.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 41 | 61 | $21,472 | $3,300 | 15.4% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 15 | 8,160 | $14,804 | $3,241 | 21.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $16,038 | $2,951 | 18.4% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 132 | 152 | $20,520 | $2,691 | 13.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 20 | $12,080 | $2,655 | 22.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 48 | 51 | $21,726 | $2,467 | 11.4% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 17 | 670 | $6,043 | $2,404 | 39.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 16 | $14,032 | $2,246 | 16.0% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 13 | 280 | $12,438 | $2,057 | 16.5% |
About Dr. Hemant Murthy, M.D
Dr. Hemant Murthy, M.D is a Hematology & Oncology healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/25/2008. The National Provider Identifier (NPI) number assigned to this provider is 1518129188.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hemant Murthy, M.D has received a total of $24,763 in payments from pharmaceutical and medical device companies, with $11,342 received in 2024. These payments were reported across 49 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($18,049).
As a Medicare-enrolled provider, Murthy has provided services to 8,547 Medicare beneficiaries, totaling 239,748 services with total Medicare billing of $4.2M. Data is available for 4 years (2020–2023), covering 215 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Jacksonville, FL
- Active Since 06/25/2008
- Last Updated 09/02/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1518129188
Products in Payments
- Reblozyl (Drug) $4,225
- VONJO (Drug) $4,112
- Venclexta (Biological) $196.85
- MOZOBIL (Drug) $195.71
- Yescarta (Drug) $185.25
- Soliris (Drug) $150.00
- DEFITELIO (Drug) $128.00
- KYMRIAH (Drug) $126.95
- REZUROCK (Drug) $121.86
- ELREXFIO (Drug) $114.53
- FOTIVDA (Drug) $99.99
- KYMRIAH (Biological) $96.68
- Blincyto (Biological) $29.42
- Kyprolis (Biological) $29.41
- Zydelig (Drug) $28.45
- Zevalin (Drug) $27.11
- JAKAFI (Drug) $26.29
- VYXEOS (Drug) $18.39
- EMPLICITI (Biological) $13.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Jacksonville
Arnab Basu, Md, MD
Hematology & Oncology — Payments: $345,058
Hematology & Oncology $345,058
Edith Perez, Md, MD
Hematology & Oncology — Payments: $282,574
Hematology & Oncology $282,574
Saranya Chumsri, Md, MD
Hematology & Oncology — Payments: $259,129
Hematology & Oncology $259,129
Sikander Ailawadhi, Md, MD
Hematology & Oncology — Payments: $244,554
Hematology & Oncology $244,554
James Foran, Md, MD
Hematology & Oncology — Payments: $157,939
Hematology & Oncology $157,939
Dr. Gregory Pennock, Md, MD
Hematology & Oncology — Payments: $133,778
Hematology & Oncology $133,778